Pan-cancer landscape of homologous recombination deficiency

Abstract

Homologous recombination deficiency (HRD) results in impaired double strand break repair and is a frequent driver of tumorigenesis. Here, we develop a genome-wide mutational scar-based pan-cancer Classifier of HOmologous Recombination Deficiency (CHORD) that can discriminate BRCA1 - and BRCA2 -subtypes. Analysis of a metastatic ( n = 3,504) and primary ( n = 1,854) pan-cancer cohort reveals that HRD is most frequent in ovarian and breast cancer, followed by pancreatic and prostate cancer. We identify biallelic inactivation of BRCA1 , BRCA2 , RAD51C or PALB2 as the most common genetic cause of HRD, with RAD51C and PALB2 inactivation resulting in BRCA2 -type HRD. We find that while the specific genetic cause of HRD is cancer type specific, biallelic inactivation is predominantly associated with loss-of-heterozygosity (LOH), with increased contribution of deep deletions in prostate cancer. Our results demonstrate the value of pan-cancer genomics-based HRD testing and its potential diagnostic value for patient stratification towards treatment with e.g. poly ADP-ribose polymerase inhibitors (PARPi).

References 37

1. 1.

   Lord CJ, Ashworth A. BRCAness revisited. Nat. Rev. Cancer. 2016;16:110-120.

   Not in our library10.1038/nrc.2015.21

2. 2.

   Nielsen F, van Overeem Hansen T, Sørensen C. Hereditary breast and ovarian cancer: new genes in confined pathways. Nat Rev Cancer. 2016;16:599-612.

   Not in our library10.1038/nrc.2016.72

3. 3.

   Audeh MW, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376:245-251.

   Not in our library10.1016/s0140-6736(10)60893-8

4. 4.

   Mateo J, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med. 2015;373:1697-1708.

   Not in our library10.1056/nejmoa1506859

5. 5.

   Hoppe MM, Sundar R, Tan DSP, Jeyasekharan AD. Biomarkers for homologous recombination deficiency in cancer. JNCI J. Natl Cancer Inst. 2018;110:704-713.

   Not in our library10.1093/jnci/djy085

6. 6.

   Van Hoeck A, Tjoonk NH, van Boxtel R, Cuppen E. Portrait of a cancer: mutational signature analyses for cancer diagnostics. BMC Cancer. 2019;19:457.

   Not in our library10.1186/s12885-019-5677-2

7. 7.

   Sfeir A, Symington LS. Microhomology-mediated end joining: a back-up survival mechanism or dedicated pathway? Trends Biochem. Sci. 2015;40:701-714.

   Not in our library10.1016/j.tibs.2015.08.006

8. 8.

   Nik-Zainal S, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016;534:47-54.

   Not in our library10.1038/nature17676

9. 9.

   Davies H, et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat. Med. 2017;23:517-525.

   Not in our library10.1038/nm.4292

10. 10.

    Degasperi A, et al. A practical framework and online tool for mutational signature analyses show intertissue variation and driver dependencies. Nat. Cancer. 2020;1:249-263.

    Not in our library10.1038/s43018-020-0027-5

11. 11.

    Nones K, et al. Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers. Ann. Oncol. 2019;30:1071-1079.

    Not in our library10.1093/annonc/mdz132

12. 12.

    Staaf J, et al. Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. Nat. Med. 2019;25:1526-1533.

    Not in our library10.1038/s41591-019-0582-4

13. 13.
    Pan-cancer whole-genome analyses of metastatic solid tumours · 2019

    No notice
14. 14.
    Pan-cancer analysis of whole genomes · 2020

    Corrected
15. 15.
    Double-slit photoelectron interference in strong-field ionization of the neon dimer · 2019

    No notice
16. 16.

    Pich O, et al. The mutational footprints of cancer therapies. Nat. Genet. 2019;51:1732-1740.

    Not in our library10.1038/s41588-019-0525-5

17. 17.
    A Compendium of Mutational Signatures of Environmental Agents · 2019

    No notice
18. 18.
    Mutational signatures of ionizing radiation in second malignancies · 2016

    No notice
19. 19.
    5-Fluorouracil treatment induces characteristic T>G mutations in human cancer · 2019

    No notice
20. 20.

    Polak P, et al. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. Nat. Genet. 2017;49:1476-1486.

    Not in our library10.1038/ng.3934

21. 21.

    Jonsson P, et al. Tumour lineage shapes BRCA-mediated phenotypes. Nature. 2019;571:576-579.

    Not in our library10.1038/s41586-019-1382-1

22. 22.

    Póti Á, et al. Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents. Genome Biol. 2019;20:240.

    Not in our library10.1186/s13059-019-1867-0

23. 23.

    Chun J, Buechelmaier ES, Powell SN. Rad51 paralog complexes BCDX2 and CX3 act at different stages in the BRCA1-BRCA2-dependent homologous recombination pathway. Mol. Cell. Biol. 2013;33:387-395.

    Not in our library10.1128/mcb.00465-12

24. 24.

    Zhao W, et al. BRCA1–BARD1 promotes RAD51-mediated homologous DNA pairing. Nature. 2017;550:360-365.

    Not in our library10.1038/nature24060

25. 25.

    Cantor SB, Guillemette S. Hereditary breast cancer and the BRCA1-associated FANCJ/BACH1/BRIP1. Future Oncol. Lond. Engl. 2011;7:253-261.

    Not in our library10.2217/fon.10.191

26. 26.
    The BRCA1-Interacting Protein Abraxas Is Required for Genomic Stability and Tumor Suppression · 2014

    Not checked
27. 27.

    Folias A, et al. BRCA1 interacts directly with the Fanconi anemia protein FANCA. Hum. Mol. Genet. 2002;11:2591-2597.

    Not in our library10.1093/hmg/11.21.2591

28. 28.

    Quigley DA, et al. Genomic hallmarks and structural variation in metastatic prostate cancer. Cell. 2018;174:758-769.e9.

    Not in our library10.1016/j.cell.2018.06.039

29. 29.

    Golan T, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic. Cancer N. Engl. J. Med. 2019;381:317-327.

    Not in our library10.1056/nejmoa1903387

30. 30.

    Pilarski R, et al. The Role of BRCA Testing in Hereditary Pancreatic and Prostate Cancer Families. Am. Soc. Clin. Oncol. Educ. Book. 2019;39:79-86.

    Not in our library10.1200/edbk_238977

31. 31.

    Chopra N, et al. Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer. Nat. Commun. 2020;11:1-12.

    Not in our library10.1038/s41467-020-16142-7

32. 32.

    Arora, K. & Barbieri, C. Molecular subtypes of prostate cancer. Curr. Oncol. Rep. 20, 58 (2018).

    Not in our library10.1007/s11912-018-0707-9

33. 33.

    Tariq N-A, McNamara M, Valle J. Biliary tract cancers: current knowledge, clinical candidates and future challenges. Cancer Manag. Res. 2019;11:2623-2642.

    Not in our library10.2147/cmar.s157092

34. 34.

    Sakai W, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2 -mutated cancers. Nature. 2008;451:1116-1120.

    Not in our library10.1038/nature06633

35. 35.

    Edwards SL, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature. 2008;451:1111-1115.

    Not in our library10.1038/nature06548

36. 36.

    Nangalia J, Campbell PJ. Genome sequencing during a patient’s journey through cancer. N. Engl. J. Med. 2019;381:2145-2156.

    Not in our library10.1056/nejmra1910138

37. 37.

    Cameron, D. L. et al. GRIDSS, PURPLE, LINX: unscrambling the tumor genome via integrated analysis of structural variation and copy number. bioRxiv.10.1101/781013 (2019).

    Not in our library

Cited by papers we hold 10

• Insights for precision oncology from the integration of genomic and clinical data of 13,880 tumors from the 100,000 Genomes Cancer Programme · 2024
  No notice
• Pan-cancer whole-genome comparison of primary and metastatic solid tumours · 2023
  No notice
• Single-cell genomic variation induced by mutational processes in cancer · 2022
  No notice
• Depiction of Aging-Based Molecular Phenotypes With Diverse Clinical Prognosis and Immunological Features in Gastric Cancer · 2022
  Not checked
• Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype · 2022
  Not checked
• Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants · 2022
  No notice
• Ovarian cancer mutational processes drive site-specific immune evasion · 2022
  No notice
• MutationalPatterns: the one stop shop for the analysis of mutational processes · 2022
  No notice
• Signatures of copy number alterations in human cancer · 2022
  No notice
• Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis · 2021
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.